HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 3851-3860

  Lee, Kyeong Eun ^a   Mulky, Alok ^a   Yuen, Wendy ^a,c   Martin, Thomas D ^a   Meyerson, Nicholas R ^b   Choi, Laura ^a   Yu, Hyun ^a   Sawyer, Sara L ^b   KewalRamani, Vineet N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 6; EFAVIRENZ; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; CODON; CONTROLLED STUDY; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS REPLICATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CAPSID; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PRIMATES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE; PRIMATES;

EID: 84861303010     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06607-11     Document Type: Article

References (41)

1. Ambrose Z, et al. Human immunodeficiency virus type 1 (HIV-1) capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J. Virol., in press.
2. Bartz SR, Vodicka MA. 1997. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12:337-342.
3. Besnier C, Takeuchi Y, Towers G. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U. S. A. 99:11920-11925.
4. Best S, Le Tissier P, Towers G, Stoye JP. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382:826-829.
5. Blair WS, et al. 2010. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS pathogens 6:e1001220.
6. Cowan S, et al. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U. S. A. 99:11914-11919.
7. Dettwiler S, Aringhieri C, Cardinale S, Keller W, Barabino SM. 2004. Distinct sequence motifs within the 68-kDa subunit of cleavage factor Im mediateRNAbinding, protein-protein interactions, and subcellular localization. J. Biol. Chem. 279:35788-35797.
8. Dismuke DJ, Aiken C. 2006. Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J. Virol. 80:3712-3720.
9. Duggal NK, Malik HS, Emerman M. 2011. The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J. Virol. 85:11361-11371.
10. Fassati A, Goff SP. 2001. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75:3626-3635.
11. Ganser-Pornillos BK, et al. 2011. Hexagonal assembly of a restricting TRIM5alpha protein. Proc. Natl. Acad. Sci. U. S. A. 108:534-539.
12. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-394.
13. Hilditch L, et al. 2011. Ordered assembly of murine leukemia virus capsid protein on lipid nanotubes directs specific binding by the restriction factor, Fv1. Proc. Natl. Acad. Sci. U. S. A. 108:5771-5776.
14. Hofmann W, et al. 1999. Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 73:10020-10028.
15. Jolicoeur P. 1979. The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Curr. Top. Microbiol. Immunol. 86:67-122.
16. Julias JG, Ferris AL, Boyer PL, Hughes SH. 2001. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J. Virol. 75:6537-6546.
17. Karolchik D, et al. 2003. The UCSC Genome Browser database. Nucleic Acids Res. 31:51-54.
18. Lee K, et al. 2010. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7:221-233.
19. McDonald D, et al. 2002. Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 159:441-452.
20. Meyerson NR, Sawyer SL. 2011. Two-stepping through time: mammals and viruses. Trends Microbiol. 19:286-294.
21. Munk C, Brandt SM, Lucero G, Landau NR. 2002. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. U. S. A. 99:13843-13848.
22. Nisole S, Lynch C, Stoye JP, Yap MW. 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U. S. A. 101:13324-13328.
23. Onishi M, et al. 1996. Applications of retrovirus-mediated expression cloning. Exp. Hematol. 24:324-329.
24. Pincus T, Rowe WP, Lilly F. 1971. A major genetic locus affecting resistance to infection with murine leukemia viruses. II. Apparent identity to a major locus described for resistance to friend murine leukemia virus. J. Exp. Med. 133:1234-1241.
25. Rein A, Kashmiri SV, Bassin RH, Gerwin BL, Duran-Troise G. 1976. Phenotypic mixing between N- and B-tropic murine leukemia viruses: infectious particles with dual sensitivity to Fv-1 restriction. Cell 7:373-379.
26. Ruegsegger U, Blank D, Keller W. 1998. Human pre-mRNA cleavage factor Im is related to spliceosomal SR proteins and can be reconstituted in vitro from recombinant subunits. Mol. Cell 1:243-253.
27. Sartini BL, Wang H, Wang W, Millette CF, Kilpatrick DL. 2008. Pre-messenger RNA cleavage factor I (CFIm): potential role in alternative polyadenylation during spermatogenesis. Biol. Reprod. 78:472-482.
28. Sawyer SL, Emerman M, Malik HS. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2:E275.
29. Sawyer SL, Wu LI, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U. S. A. 102:2832-2837.
30. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
31. Schindler J, Gautsch JW, Lerner RA, Hopkins N. 1981. Biochemical analysis of the p30's of N-, B-, and B leads to NB-tropic murine leukemia viruses of BALB/c origin. J. Virol. 39:703-712.
32. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. 2011. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85:542-549.
33. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
34. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882.
35. Towers G, et al. 2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U. S. A. 97:12295-12299.
36. Towers GJ, et al. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143.
37. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. 2006. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U. S. A. 103:7465-7470.
38. Yang Q, Coseno M, Gilmartin GM, Doublie S. 2011. Crystal structure of a human cleavage factor CFI(m)25/CFI(m)68/RNA complex provides an insight into poly(A) site recognition and RNA looping. Structure 19:368-377.
39. Yang Z. 1997. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput. Appl. Biosci. 13:555-556.
40. Yap MW, Dodding MP, Stoye JP. 2006. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J. Virol. 80:4061-4067.
41. Zhou L, et al. 2011. Transportin 3 promotes a nuclear maturation step required for efficient HIV-1 integration. PLoS Pathog. 7:e1002194.